Hsu Ya-Fen, Sheu Joen-Rong, Lin Chien-Huang, Yang De-Shin, Hsiao George, Ou George, Chiu Pei-Ting, Huang Yu-Han, Kuo Wen-Hsin, Hsu Ming-Jen
Division of General Surgery, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Biochim Biophys Acta. 2012 Feb;1820(2):104-15. doi: 10.1016/j.bbagen.2011.11.011. Epub 2011 Dec 1.
Elevated levels of survivin and histone deacetylases (HDACs) are often found over-expressed in human cancers, including colorectal cancer, and have been implicated in tumorigenesis. HDAC inhibition induces growth arrest and cell death in various transformed cell; however, the mechanisms by which this reduces cell viability in colorectal cancer cells remain unexplained.
We explored the actions of two HDAC inhibitors, trichostatin A (TSA) and sirtinol, in HT29 colon cancer cells.
TSA and sirtinol induced apoptosis and inhibited cell proliferation in HT29 cells. These results are associated with the modulation of survivin. Survivin promoter luciferase activity and Sp1, a transcription factor that contributes to survivin expression, were suppressed in cells exposed to TSA or sirtinol. TSA and sirtinol also activated p38 mitogen-activated protein kinase (p38MAPK) and AMP-activated protein kinase (AMPK). Inhibitors of p38MAPK or AMPK signaling abrogated TSA and sirtinol's effects of decreasing cell viability. Survivin promoter luciferase activity in the presence of TSA or sirtinol was restored by AMPK dominant negative mutant or p38MAPK inhibitor. Furthermore, Sp1 binding to the survivin promoter region decreased while p63 binding to the promoter region increased after TSA or sirtinol exposure.
We report a p38MAPK- and AMPK-mediated downregulation of survivin, and its functional correlation with decreased colon cancer cell viability in the presence of HDAC inhibitor. p63 and Sp1 may also contribute to TSA and sirtinol actions.
This study delineates, in part, the underlying mechanisms of TSA and sirtinol in decreasing survivin expression and subsequent colon cancer cell viability.
在包括结直肠癌在内的人类癌症中,经常发现存活素和组蛋白去乙酰化酶(HDACs)水平升高,并且它们与肿瘤发生有关。HDAC抑制在各种转化细胞中诱导生长停滞和细胞死亡;然而,其降低结直肠癌细胞活力的机制仍未阐明。
我们探究了两种HDAC抑制剂曲古抑菌素A(TSA)和sirtinol在HT29结肠癌细胞中的作用。
TSA和sirtinol诱导HT29细胞凋亡并抑制其增殖。这些结果与存活素的调节有关。在暴露于TSA或sirtinol的细胞中,存活素启动子荧光素酶活性以及有助于存活素表达的转录因子Sp1受到抑制。TSA和sirtinol还激活了p38丝裂原活化蛋白激酶(p38MAPK)和AMP活化蛋白激酶(AMPK)。p38MAPK或AMPK信号通路的抑制剂消除了TSA和sirtinol降低细胞活力的作用。在存在AMPK显性负性突变体或p38MAPK抑制剂的情况下,TSA或sirtinol存在时的存活素启动子荧光素酶活性得以恢复。此外,暴露于TSA或sirtinol后,Sp1与存活素启动子区域的结合减少,而p63与启动子区域的结合增加。
我们报告了p38MAPK和AMPK介导的存活素下调及其在HDAC抑制剂存在下与结直肠癌细胞活力降低的功能相关性。p63和Sp1也可能有助于TSA和sirtinol的作用。
本研究部分阐述了TSA和sirtinol降低存活素表达及随后降低结肠癌细胞活力的潜在机制。